Conversely, certain experiments indicate that NEPC undergoes transdifferentiation from prostatic adenocarcinoma, supported by the detection of prostate cancer-specific mutations (for example, ERG rearrangements) and gene amplifications (for example, AURKA and MYCN) in both subtypes. The gene discussed is MYCN; the disease is prostate cancer.